DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Diakonos Oncology Corporation, now recruiting.
Overview
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) is a phase 2 interventional study registered as NCT06805305 by Diakonos Oncology Corporation, with 180 participants planned, started 2025-03-17 and due to reach its primary completion in 2030-03. Interventions recorded: DOC1021, Tumor resection, Temodar (Temozolomide) and SOC cranial radiation.
Similar pages
not linked directly; found by shared links- TrialDOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Shares DOC1021, Diakonos Oncology and the tag pipeline.
- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialPh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialSonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialGlioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialSafety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.